Bio-Techne Corp (TECH) has been fluctuating in the stock market with a mixture of both potential investment opportunities and shares sales. Some promoting factors include Norges Bank, Cresset Asset Management, and Granite Investment Partners LLC increasing their holdings in the company. Also, a partnership with Oxford Nanopore Technologies to expand their genetic portfolio through 2032 has been announced which might boost the company's long-term growth. However, Brown Capital Management, SG Americas Securities and Mitsubishi UFJ Asset Management Co. Ltd. have significantly reduced their stock holdings in the company. Some reports suggest undervaluation and lackluster earnings, highlighting Q1 and Q3 Earnings where revenues fell short of estimated figures, affecting its stock performance negatively. Despite that, there were several instances of optimistic market sentiment, with AI-designed NovoBody Duo Molecules being licensed to expand its recombinant protein portfolio. Additionally, Bio-Techne has announced that it will present at upcoming investor conferences.
Bio-Techne Corp TECH News Analytics from Thu, 24 Apr 2025 07:00:00 GMT to Fri, 05 Dec 2025 10:07:27 GMT -
Rating 1
- Innovation 5
- Information 8
- Rumor 3
